Compare
Anika Therapeutics, Inc. vs Orasure Technologies Inc vs Kestra Medical Technologies, Ltd. vs Xtant Medical Holdings, Inc.
| Latest fiscal year | Anika Therapeutics, Inc. ANIK | Orasure Technologies Inc OSUR | Kestra Medical Technologies, Ltd. KMTS | Xtant Medical Holdings, Inc. XTNT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-04-30 | 2025-12-31 |
| Revenue | $112.82M | $115.02M | $95.13M | $133.93M |
| Revenue growth (YoY) | -5.9% | -38.1% | +59.0% | +14.2% |
| Gross margin | 56.6% | 41.9% | 51.4% | 62.9% |
| Operating margin | -9.8% | -62.6% | -141.6% | 5.4% |
| Net margin | -9.6% | -59.8% | -138.4% | 3.7% |
| Net income | -$10.88M | -$68.73M | -$131.61M | $4.97M |
| EPS (Diluted) | -$0.76 | -$0.94 | -$2.43 | $0.03 |
| Operating cash flow | $11.19M | -$49.02M | -$81.70M | $12.55M |
| Free cash flow | $4.36M | -$53.22M | -$116.59M | $10.16M |
| Cash & equivalents | $57.48M | $199.28M | $99.71M | $17.05M |
| Total assets | $190.27M | $403.17M | $358.46M | $94.14M |
| Total liabilities | n/a | $62.34M | $98.81M | $43.19M |
| Shareholders' equity | $143.47M | $340.83M | $259.66M | $50.95M |
| Return on year-end equity | -7.6% | -20.2% | -50.7% | 9.8% |
| Shares outstanding | 13.89M | 70.39M | 58.38M | 140.04M |
Revenue, most recent five fiscal years
| Fiscal year | Anika Therapeutics, Inc. | Orasure Technologies Inc | Kestra Medical Technologies, Ltd. | Xtant Medical Holdings, Inc. |
|---|---|---|---|---|
| Latest | $112.82M Ended 2025-12-31 | $115.02M Ended 2025-12-31 | $95.13M Ended 2026-04-30 | $133.93M Ended 2025-12-31 |
| 1 year earlier | $119.91M Ended 2024-12-31 | $185.83M Ended 2024-12-31 | $59.81M Ended 2025-04-30 | $117.27M Ended 2024-12-31 |
| 2 years earlier | $120.79M Ended 2023-12-31 | $405.47M Ended 2023-12-31 | $27.81M Ended 2024-04-30 | $91.30M Ended 2023-12-31 |
| 3 years earlier | $113.83M Ended 2022-12-31 | $387.48M Ended 2022-12-31 | n/a | $57.97M Ended 2022-12-31 |
| 4 years earlier | $147.79M Ended 2021-12-31 | $233.67M Ended 2021-12-31 | n/a | $55.26M Ended 2021-12-31 |